High Growth Tech Stocks To Explore This November 2024

In This Article:

As global markets experience broad-based gains with smaller-cap indexes outperforming large-caps, investors are closely watching the Federal Reserve's upcoming decisions on interest rates amid a strong U.S. labor market and rising home sales. In this environment, identifying high growth tech stocks involves focusing on companies that can capitalize on technological advancements and maintain robust performance despite geopolitical tensions and economic uncertainties.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Material Group

20.45%

24.01%

★★★★★★

Pharma Mar

25.97%

56.89%

★★★★★★

Ascelia Pharma

76.15%

47.16%

★★★★★★

Waystream Holding

22.46%

109.25%

★★★★★★

JNTC

20.52%

57.26%

★★★★★★

TG Therapeutics

34.66%

56.48%

★★★★★★

Elliptic Laboratories

65.73%

103.55%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

Alnylam Pharmaceuticals

22.45%

70.66%

★★★★★★

Travere Therapeutics

31.70%

72.51%

★★★★★★

Click here to see the full list of 1300 stocks from our High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Valneva

Simply Wall St Growth Rating: ★★★★★☆

Overview: Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet needs, with a market cap of €332.86 million.

Operations: Valneva SE generates revenue primarily through the development, manufacturing, and commercialization of vaccines targeting infectious diseases with significant unmet needs. The company's focus on prophylactic vaccines positions it within a niche market segment in the pharmaceutical industry.

Valneva has shown a remarkable turnaround with its recent earnings, posting a net income of €24.74 million for the nine months ended September 2024, a significant shift from a net loss of €69.27 million in the previous year. This financial recovery is underscored by an impressive 24.6% increase in revenue year-over-year. The company's commitment to innovation is evident in its R&D efforts, which are strategically aligned with addressing global health threats like shigellosis and chikungunya; diseases that currently lack effective vaccines. Valneva's R&D expenses have been pivotal, enabling them to advance their pipeline significantly and secure Fast Track designation from the FDA for their lead vaccine candidate S4V2, highlighting its potential to meet urgent medical needs worldwide.